Journal of Ophthalmic Inflammation and Infection (Mar 2022)

Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report

  • Jeremy P. M. Flanagan,
  • Michael Ng,
  • Awet Z. Kibrom,
  • Robin J. A. Filshie,
  • Richard J. Stawell,
  • Roderick F. O’Day

DOI
https://doi.org/10.1186/s12348-022-00288-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Primary choroidal lymphoma is a rare, slowly progressive intraocular malignancy. Most are low grade B cell lymphomas, often involving tissues adjacent to the choroid such as the subconjunctival space, lacrimal gland or orbit. Ideally, these lesions are biopsied to establish histopathological diagnosis. The most accessible ocular structure is biopsied. Obtaining tissue by transvitreal choroidal biopsy imparts a small but significant risk of ocular morbidity, including the need for multiple surgeries, retinal detachment and vision loss. External beam radiotherapy (EBRT) is a common and effective treatment of low-grade lymphomas. EBRT has been found to very successfully treat primary marginal zone lymphomas of the ocular adnexa, which are typically of the same cell type as most primary choroid lymphomas. Ultra-low dose EBRT, most commonly using a total dose of 4 Gy, has been shown to be as effective as higher doses of radiotherapy for follicular or marginal zone lymphomas. The use of this low dose regimen for conjunctival lymphomas has been recently explored. The role of EBRT, and especially ultra-low dose EBRT, for treatment of primary choroidal lymphoma has been confined to case reports. We describe a case of presumed primary choroidal lymphoma diagnosed on clinical findings alone as the risks of ocular biopsy were deemed too high, and report outcome following treatment with ultra-low dose EBRT.